Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions

March 20, 2021 updated by: Renishaw

A Long-Term Follow-up Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Implanted With the DDS and/or Who Received Treatment in the Main Study and/or Extension Study

This study is a follow up to the HP-CD-CL-2002 clinical study. It evaluates the long-term safety in patients with Parkinson's disease after implantation of an investigational drug delivery system (DDS) with or without infusions of CDNF. All patients will have at least the port explanted.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

A patients participation in the study will last for up to 4 years and will include up to nine visits:

  • Screening (1 visit, same as HP-CD-CL-2003 End-of-Study visit)
  • Pre-surgery / explantation surgery / post-surgery (3 visits)
  • Safety (4 visits)
  • DAT-PET (Dopamine Transporter - Positron Emission Tomography) examination (1 visit)
  • End-of-study visit (1 visit)

Study examinations and assessments:

  • Physical examination: pulse rate, blood pressure, temperature, body weight and height, body mass index (BMI), neurological exam
  • ECG (electrocardiography) and blood and urine tests
  • Pregnancy tests for women of childbearing age
  • Completion of a patient diary to record mobility and time asleep
  • Parkinson's Kinetigraph (PKGTM) Data Logger: a watch-type movement recording device
  • Questionnaires, rating scales and forms: quality of life, mood, memory, impulse control, mental health.
  • Magnetic resonance imaging (MRI)
  • Positron emission tomography scans (PET)
  • Skin condition over any remaining implanted subcutaneous portion of the device.
  • Skin healing after port / device removal.

For more information: https://treater.eu/clinical-study/

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Helsinki, Finland, 00029
        • Helsinki University Hospital
      • Lund,, Sweden, 221 85
        • Skane University Hospital
      • Stockholm, Sweden, 14186
        • Karolinksa University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

31 years to 71 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Completion of visit 4 (implantation of DDS) within main study HP-CD-CL-2002.
  2. Patients who:

    • Discontinued main study after visit 4 of main study or discontinued extension study.
    • Received 6 doses in main study but didn't participate in extension study.
    • Received 12 doses including extension study.
  3. Provision of informed consent.

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: No Arm
As this is the follow up study, there are no arms
Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of treatment-emergent adverse events (AEs)[safety-tolerability]
Time Frame: Until study completion, up to month 58
Total number, causality and severity of adverse events at any time during the study period
Until study completion, up to month 58
Change in Electrocardiogram (ECG): Ventricular rate (bpm), [safety-tolerability]
Time Frame: Week 71 and Month 25
Changes in electrical activity of heartbeat measured by electrocardiogram: Ventricular rate (bpm),
Week 71 and Month 25
Change in Electrocardiogram (ECG): PR (pulse rate) interval, qRS duration, QT, QTc (msec) [safety-tolerability]
Time Frame: Week 71 and Month 25
Changes in electrical activity of heartbeat measured by electrocardiogram: PR interval (msec), QRS duration (msec), QT (msec), QTc (msec)
Week 71 and Month 25
Change in Beck Depression Inventory (BDI) score [safety-tolerability]
Time Frame: Week 71 and Month 25
Assessment of change in depression using Beck Depression Inventory (BDI) score: Sadness: Pessimism; Past Failure; Loss of pleasure; Guilty feelings; Punishment Feelings; Self-dislike; Self-criticalness;Suicidal thoughts or wishes; Crying; Agitation; Loss of interest; Indecisiveness;Worthlessness; Loss of energy; Changes in sleeping pattern; Irritability; Changes in appetite; Concentration difficulty; Tiredness or fatique; Loss of interest in sex. Rated on a 4-point scale ranging from 0 to 3 based on severity of each item (0=low intensity; 3=highest intensity). The maximum total score is 63.
Week 71 and Month 25
Change in Questionnaire for impulsive-compulsive disorder in Parkinson's disease rating scale (QUIP_RS) [safety-tolerability]
Time Frame: Week 71 and Month 25

Assessment of changes in impulsive-compulsive disorders using QUIP_RS. Questions scored 0-4 (0=never; 4=very often) on gambling, sex, buying, eating, performing tasks/hobbies, repeating simple activities, and taking Parkinson's disease medication. Total QUIP-RS Score 0-112

Assessment of changes in impulsive-compulsive disorders using QUIP_RS. Questions scored 0-4 (0=never; 4=very often) on gambling, sex, buying, eating, performing tasks/hobbies, repeating simple activities, and taking Parkinson's disease medication. Total QUIP-RS Score 0-112

Assessment of changes in impulsive-compulsive disorders using QUIP_RS. Questions scored 0-4 (0=never; 4=very often) on gambling, sex, buying, eating, performing tasks/hobbies, repeating simple activities, and taking Parkinson's disease medication. Total QUIP-RS Score 0-112

Week 71 and Month 25
Change in Montreal cognitive assessment (MoCA) [safety-tolerability]
Time Frame: Week 71 and Month 25
Assessment of change in cognitive domains using MoCA test: attention and, concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The total possible score is 30 points; a score of 26 or above is considered normal.
Week 71 and Month 25
Changes in physical examination: anatomic findings [safety-tolerability]
Time Frame: Week 71, and Months 25, 34, 58
Changes in anatomic findings found in physical examination of the following body systems: general inspection/upper extremities; head, eyes, ears, nose, throat, and superficial cervial lymph notes; neck, shoulders, back; chest and lungs; cardiovascular; abdomen; lower extremities
Week 71, and Months 25, 34, 58
Changes in physical examination: clinical standard neurological examination
Time Frame: Week 71, and Months 25, 34, 58
A clinical standard neurological examination by study investigator. Changes in motor function, sensory function, cranial nerve function (visual fields), cortical functions and reflexes are followed in the examination, scored as normal - abnormal without clinical relevance - abnormal with clinical relevance
Week 71, and Months 25, 34, 58
Changes in vital signs: blood pressure [safety-tolerability]
Time Frame: Weeks 55, 57, 58, 75
Changes in blood pressure during the study , measured as systolic and diastolic blood pressure (in mmHg)
Weeks 55, 57, 58, 75
Changes in vital signs: pulse rate [safety-tolerability]
Time Frame: Weeks 55, 57, 58, 75
Changes in pulse rate during the study (in beats per minute)
Weeks 55, 57, 58, 75
Changes in vital signs: body temperature [safety-tolerability]
Time Frame: Weeks 55, 57, 58, 75
Changes in body temperature during the study (in degrees celcius)
Weeks 55, 57, 58, 75
Changes in vital signs: body weight [safety-tolerability]
Time Frame: Weeks 55, 57, 58, 75
Changes in body weight during the study (in kilograms)
Weeks 55, 57, 58, 75
Changes in vital signs: body mass index (BMI) [safety-tolerability]
Time Frame: Weeks 55, 57, 58, 75
Changes in body mass index during the study (in kg/m^2)
Weeks 55, 57, 58, 75
Changes in clinical laboratory safety screen: clinical chemistry [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in laboratory variables for clinical chemistry (Na, K, Urea, creatinine, creatine kinase, Ca, Bilirubin, IgG (Immunoglobulin G), Albumin, ALP(Alkaline phosphatase), ALT (Alanine transaminase), AST (Aspartate transaminase))
Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: haematology - haemoglobin [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in laboratory variables for haematology: hemoglobin (g/L). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: haematology - haematocrit [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in laboratory variables for haematology: hematocrit (%, ratio of red blood cell volume to total blood volume). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: haematology - red blood cell (RBC) count [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in laboratory variables for haematology: RBC count (10E12/L). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: mean cell volume (MCV) of red blood cells [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in laboratory variables for haematology: MCV of red blood cells (fL). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: mean cell haemoglobin of RBC (MHC) [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in laboratory variables for haematology: MCH (Mean cell hemoglobin) (pg). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: Platelet count [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in laboratory variables for haematology: Platelet count (10E9/L). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: white blood call (WBC) count [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in laboratory variables for haematology: Cell counts (10E9/L) for total WBC, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: activated partial thromboplastin time (aPTT) [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in laboratory variables for haematology: aPTT (sec) . Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: International Normalised Ratio (INR) [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in laboratory variables for haematology: INR (standardized prothrombin time) to determine the effects of oral anticoagulants on the clotting system. Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Weeks 53, 55, 57, 58, 71 and Months 25, 34, 58
Changes in clinical laboratory safety screen: urinanalysis [safety-tolerability]
Time Frame: Weeks 53, 55, 57, 58, 71 and Month 25
Changes in laboratory variables for urinanalysis (blood/erythrocytes, glucose, ketones, leukocytes, nitrites, pH, protein) studied by dipstick and scored 0-3. Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance".
Weeks 53, 55, 57, 58, 71 and Month 25
Formation of anti-CDNF antibodies [safety-tolerability]
Time Frame: Weeks 58, 78 and Month 25
Formation and change in anti-CDNF antibody concentration (in ng/ml).
Weeks 58, 78 and Month 25
Device related occurrence of adverse device effects [safety-tolerability]
Time Frame: Week 49 and Month 58
Occurrence of adverse device effects (ADE) at any time of the study period, for either the whole system or the individual sub systems (guide tubes/catheters, subcutaneous components, port), serious adverse device effect (SADE) including long term effects, neurological deficit (seizures), infection (local to components, in CNS), severe skin breakdown or necrosis requiring component removal life threatening or major (requiring intervention) intracerebral haemorrhage.
Week 49 and Month 58

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in UPDRS (Unified Parkinson's Disease Rating Scale) Part III motor score [efficacy]
Time Frame: Week 71 and Month 25
Changes in severity of PD (Parkinson's disease) motor symptoms assessed by UPDRS Part III motor scores (each scored 0-4; 0=none, 4=severe): Speech; facial expression; tremor a rest; Tremor of hands; rigidity; firger taps; hand movelents; alternating movement of hands; leg agility; rising from chair; posture; gait; postural stability; body bradykinesia and hypokinesia. The total score, the sum of scores received from 27 assessments, is 0 - 108
Week 71 and Month 25
Change in TUG (Timed Up and Go) test [efficacy]
Time Frame: Week 71 and Month 25
Changes in mobility assessed by TUG test (in minutes and seconds).
Week 71 and Month 25
Change in UPDRS Total score (Part I-IV) [efficacy]
Time Frame: Week 71 and Month 25
Change in severity of PD non-motor and motor symptoms assessed by UPDRS Part I-IV total scores (Parts I, II and IV in ON-state; Part III in OFF-state): Part 1 (scored 0-16) Mentation, behaviour and mood. Part 2 (scored 0-52) Activities of daily living. Part 3 (scored 0-108) Motor examination. Part 4 (scored 0-23) Complications of therapy. The total score is 0-199 (0=totally healthy; 199=worst possible).
Week 71 and Month 25
Change in home diary score [efficacy]
Time Frame: Weeks 40, 45, 49, 53, 57, 58, 61, 65, 71, and Month 25
Change in functional status of the patient's dyskinesias assessed by home diary score for three-day period. Each half hour is scored: sleep, OFF, ON without dyskinesias, ON with non-troublesome dyskinesias, ON with troublesome dyskinesias. The total time in each state over 3 days is recorded (in hours). The total "bad time" is defined as "OFF time" and "ON time with troublesome dyskinesia". The total "good time" is defined as "ON time without dyskinesia" or "ON time with non-troublesome dyskinesia".
Weeks 40, 45, 49, 53, 57, 58, 61, 65, 71, and Month 25
Change in PDQ-39 (Parkinson's Disease Questionnaire) score [efficacy]
Time Frame: Week 71 and Month 25
Changes in health and daily activity assessed by a self-administered PDQ-39 questionnaire comprising of 39 questions related to eight key areas of health in Parkinson's patients: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication and bodily discomfort. Each question is evaluated on a scale of five terms "Never", "Occasionally", "Sometimes", "Often" or "Always or cannot do at all".
Week 71 and Month 25
Change in CGI-I (Clinical Global Impression - Improvement) scale [efficacy]
Time Frame: Weeks 40, 45, 49, 53, 57, 58, 61, 65, 71, and Month 25
Change in mental status as measured by CGI-I scale rated by the clinical on a seven-point scale 1-7 (1=very much improved, 4=no change, 7=very much worse).
Weeks 40, 45, 49, 53, 57, 58, 61, 65, 71, and Month 25
Healing of patient skin after port removal
Time Frame: Month 25, 34 and 58
Any Adverse Events (AEs) or Serious Adverse Events (SAEs) related to the skin condition once the port has been removed
Month 25, 34 and 58

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in DAT (dopamine transporter)-PET imaging [exploratory]
Time Frame: Week 63
Change in caudate and putamen DAT availability using PET imaging
Week 63
Change in daily activity measurement [exploratory]
Time Frame: Weeks 58, 71 and Month 25
Change in daily activity measured by Parkinson's KinetiGraph™ (PKG™) Data Logger: dyskinesia, bradykinesia, tremor, immobility plot, fluctuation score. The PKG units are: Bradykinesia score in % from normal controls, and, Dyskinesia score in % from normal controls. The Fluctuation and Dyskinesia score (FDS) for normal controls is in the range of 7.8-12.8: a lower score indicates bradykinesia and a higher score indicates dyskinesia.
Weeks 58, 71 and Month 25

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 20, 2019

Primary Completion (Anticipated)

September 20, 2022

Study Completion (Anticipated)

March 20, 2023

Study Registration Dates

First Submitted

August 21, 2019

First Submitted That Met QC Criteria

January 10, 2020

First Posted (Actual)

January 14, 2020

Study Record Updates

Last Update Posted (Actual)

March 23, 2021

Last Update Submitted That Met QC Criteria

March 20, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.